Menu
Back to Journals » Journal of Asthma and Allergy » Call For Papers
Journal of Asthma and Allergy
ISSN: 1178-6965
The following Article Collection/ Thematic Series is currently open for submissions:
Targeted Personalized Biologic Therapies: Changing the Game in Asthma Treatment
Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Targeted Personalized Biologic Therapies: Changing the Game in Asthma Treatment” in the Journal of Asthma and Allergy.
This Collection, edited by the Editor-In-Chief Dr. Amrita Dosanjh, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
Asthma is a chronic inflammatory lung condition that results in airway obstruction and difficulty breathing. Left untreated, severe asthma flares can lead to hospitalization and even death. Typical front-line treatments of asthma include corticosteroids (which cause immunosuppression with long-term use) and bronchodilators (such as albuterol inhalers). While biologic therapy is relatively new in asthma treatment, Global Initiative For Asthma (GINA) guidelines include biologics as therapeutic options. There are several biologics currently available and in development for the treatment of asthma.
While the call is open to receive manuscripts across the broad spectrum of asthma-modulating biologics, the Editors are particularly interested in manuscripts relating to the following areas:
- Signaling pathways and cellular targets
- Novel mechanisms of action of new candidate biologics
- Anti IL-4 and IL-13 combination biologics and monoclonal antibodies
- Treatment and dosing strategies based on asthma typing
- Biologic switching and combination therapy
- Long-term efficacy and safety studies
Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission SRNMA. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros at [email protected].
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 April 2026.
Call For Papers
Editor-in-Chief: Amrita Dosanjh, MD
To see where the Journal of Asthma and Allergy is indexed online view the Journal Metrics.
What is the advantage to you of publishing in the Journal of Asthma and Allergy?
- It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
- Although the Journal of Asthma and Allergy receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
- The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. The Journal of Asthma and Allergy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
- Many authors have found that our peer reviewer’s comments substantially add to their final papers.
To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.
PubMed
The Journal of Asthma and Allergy is indexed on PubMed Central (title abbreviation: J Asthma Allergy). All published papers in this journal are submitted to PubMed for indexing straight away.
Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.
Yours sincerely
Amrita Dosanjh, MD
Editor-in-Chief
Journal of Asthma and Allergy
Email: Editor-in-Chief
Updated 11 October 2022